Skip to main navigation Skip to search Skip to main content

The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

  • Darron R. Brown
  • , Susanne K. Kjaer
  • , Kristján Sigurdsson
  • , Ole Erik Iversen
  • , Hernandez Avila Mauricio
  • , Cosette M. Wheeler
  • , Gonzalo Perez
  • , Laura A. Koutsky
  • , Eng Hseon Tay
  • , Patricía Garcia
  • , Kevin A. Ault
  • , Suzanne M. Garland
  • , Sepp Leodolter
  • , Sven Eric Olsson
  • , Grace W.K. Tang
  • , Daron G. Ferris
  • , Jorma Paavonen
  • , Marc Steben
  • , F. Xavier Bosch
  • , Joakim Dillner
    • Elmar A. Joura, Robert J. Kurman, Slawomir Majewski, Nubia Muñoz, Evan R. Myers, Luisa L. Villa, Frank J. Taddeo, Christine Roberts, Amha Tadesse, Janine Bryan, Lisa C. Lupinacci, Katherine E.D. Giacoletti, Heather L. Sings, Margaret James, Teresa M. Hesley, Eliav Barra

Research output: Contribution to journal › Article › peer-review

447   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science